[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TMEM100

Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein. Membrane Multi-pass membrane protein Perikaryon. Cytoplasm, perinuclear region. Endoplasmic reticulum. Note=Colocalized with HSPA5 in the endoplasmic reticulum (ER). Enriched in ER microsome. Colocalized with BMP4 in neural cell bodies and neural fibers of the enteric nervous system.
Domain PF16311 Transmembrane protein 100
Function

Plays a role during embryonic arterial endothelium differentiation and vascular morphogenesis through the ACVRL1 receptor-dependent signaling pathway upon stimulation by bone morphogenetic proteins, such as GDF2/BMP9 and BMP10. Involved in the regulation of nociception, acting as a modulator of the interaction between TRPA1 and TRPV1, two molecular sensors and mediators of pain signals in dorsal root ganglia (DRG) neurons. Mechanistically, it weakens their interaction, thereby releasing the inhibition of TRPA1 by TRPV1 and increasing the single-channel open probability of the TRPA1-TRPV1 complex.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001570 vasculogenesis
GO:0001701 in utero embryonic development
GO:0001837 epithelial to mesenchymal transition
GO:0003007 heart morphogenesis
GO:0003158 endothelium development
GO:0003197 endocardial cushion development
GO:0003198 epithelial to mesenchymal transition involved in endocardial cushion formation
GO:0003203 endocardial cushion morphogenesis
GO:0003272 endocardial cushion formation
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007219 Notch signaling pathway
GO:0007507 heart development
GO:0019233 sensory perception of pain
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0030509 BMP signaling pathway
GO:0030856 regulation of epithelial cell differentiation
GO:0030858 positive regulation of epithelial cell differentiation
GO:0031644 regulation of neurological system process
GO:0043491 protein kinase B signaling
GO:0044057 regulation of system process
GO:0045446 endothelial cell differentiation
GO:0045601 regulation of endothelial cell differentiation
GO:0045603 positive regulation of endothelial cell differentiation
GO:0048514 blood vessel morphogenesis
GO:0048762 mesenchymal cell differentiation
GO:0050848 regulation of calcium-mediated signaling
GO:0051930 regulation of sensory perception of pain
GO:0051931 regulation of sensory perception
GO:0060317 cardiac epithelial to mesenchymal transition
GO:0060485 mesenchyme development
GO:0060837 blood vessel endothelial cell differentiation
GO:0060842 arterial endothelial cell differentiation
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0072132 mesenchyme morphogenesis
GO:1901342 regulation of vasculature development
GO:1904018 positive regulation of vasculature development
GO:2001212 regulation of vasculogenesis
GO:2001214 positive regulation of vasculogenesis
Molecular Function -
Cellular Component GO:0043025 neuronal cell body
GO:0043204 perikaryon
GO:0044297 cell body
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TMEM100 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TMEM100 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TMEM100 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.4470.00998
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-3.0270.000296
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3060.714
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.820.325
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2940.816
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.4880.291
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2860.707
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.150.292
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7130.535
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2910.797
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9570.159
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3320.223
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TMEM100 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TMEM100. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TMEM100. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TMEM100.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TMEM100. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TMEM100 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TMEM100 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTMEM100
Nametransmembrane protein 100
Aliases FLJ10970; FLJ37856
Chromosomal Location17q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TMEM100 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.